Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016
Published Nov 09, 2016
722 pages — Published Nov 09, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape.

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and

  
Source:
Document ID
GMDHC8644IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents221
  List of Tables193
  List of Figures221
Introduction231
  Global Markets Direct Report Coverage231
Head And Neck Cancer Squamous Cell Carcinoma Overview241
Therapeutics Development252
  Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Overview251
  Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis261
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies277
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes341
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Products Glance354
  Late Stage Products351
  Clinical Stage Products361
  Early Stage Products371
  Unknown Stage Products381
Head And Neck Cancer Squamous Cell Carcinoma Products under Development by Companies3910
Head And Neck Cancer Squamous Cell Carcinoma Products under Investigation by Universities/Institutes491
Head And Neck Cancer Squamous Cell Carcinoma Companies Involved in Therapeutics Development5085
  AB Science SA501
  AbbVie Inc511
  Accelerated Pharma, Inc.521
  Acceleron Pharma, Inc.531
  Adaptimmune Therapeutics Plc541
  Advaxis, Inc.551
  Altor BioScience Corporation561
  Amgen Inc.571
  AstraZeneca Plc581
  AVEO Pharmaceuticals, Inc.591
  Bayer AG601
  Bionovis SA611
  BioNTech AG621
  Boehringer Ingelheim GmbH631
  Bristol-Myers Squibb Company641
  Calithera Biosciences, Inc.651
  CEL-SCI Corporation661
  Cellceutix Corporation671
  Celldex Therapeutics, Inc.681
  Centrose LLC691
  Critical Outcome Technologies Inc.701
  CytImmune Sciences, Inc.711
  Daiichi Sankyo Company, Limited721
  Eisai Co., Ltd.731
  Eleven Biotherapeutics Inc.741
  Eli Lilly and Company751
  Etubics Corporation761
  F. Hoffmann-La Roche Ltd.771
  G&E Herbal Biotechnology Co., Ltd.781
  GeneSegues Inc791
  Genexine, Inc.801
  Genmab A/S811
  GlaxoSmithKline Plc821
  Gliknik, Inc.831
  Glycotope GmbH841
  Hanmi Pharmaceuticals, Co. Ltd.851
  Horizon Pharma Plc861
  Immunomedics, Inc.871
  Immunovative Therapies, Ltd.881
  Incyte Corporation891
  Infinity Pharmaceuticals, Inc.901
  Innate Pharma S.A.911
  Inovio Pharmaceuticals, Inc.921
  IRX Therapeutics, Inc.931
  Johnson &Johnson941
  Kolltan Pharmaceuticals, Inc.951
  Laboratoires Pierre Fabre SA961
  Loxo Oncology, Inc.971
  Mabion SA981
  MacroGenics, Inc.991
  Marsala Biotech Inc.1001
  Mateon Therapeutics Inc1011
  MedImmune LLC1021
  Merck &Co., Inc.1031
  Merck KGaA1041
  Merrimack Pharmaceuticals, Inc.1051
  Millennium Pharmaceuticals Inc1061
  Mirati Therapeutics Inc.1071
  Molecular Partners AG1081
  Molplex Ltd.1091
  NanoCarrier Co., Ltd.1101
  Novartis AG1111
  Oncobiologics, Inc.1121
  Oncolytics Biotech Inc.1131
  Onconova Therapeutics, Inc.1141
  OncoSec Medical Incorporated1151
  Ono Pharmaceutical Co., Ltd.1161
  Panacea Biotec Limited1171
  PCI Biotech Holding ASA1181
  Pfizer Inc.1191
  Reliance Life Sciences Pvt. Ltd.1201
  Sanofi1211
  Shanghai Henlius Biotech Co., Ltd.1221
  Shionogi &Co., Ltd.1231
  Sillajen Biotherapeutics1241
  Symphogen A/S1251
  SynCore Biotechnology Co., Ltd.1261
  Takara Bio Inc.1271
  Tara Immuno-Oncology Therapeutics LLC1281
  Transgene SA1291
  UbiVac, LLC1301
  VasGene Therapeutics, Inc.1311
  VentiRx Pharmaceuticals, Inc.1321
  Virttu Biologics Limited1331
  Vyriad Inc1341
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment13530
  Assessment by Monotherapy Products1351
  Assessment by Combination Products1361
  Assessment by Target13712
  Assessment by Mechanism of Action14912
  Assessment by Route of Administration1612
  Assessment by Molecule Type1632
Drug Profiles165534
  ABBV-221 Drug Profile1651
  acalabrutinib Drug Profile1663
  AdIL-24 Drug Profile1692
  afatinib dimaleate Drug Profile17113
  AlloVax Drug Profile1842
  alpelisib Drug Profile1863
  ALT-803 Drug Profile1893
  AMG-319 Drug Profile1921
  Antibodies to Inhibit FRMD4A for Oncology Drug Profile1931
  Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile1941
  AV-203 Drug Profile1953
  avelumab Drug Profile1986
  axalimogene filolisbac Drug Profile20416
  AZD-1775 Drug Profile2203
  AZD-6738 Drug Profile2231
  AZD-9150 Drug Profile2243
  BMS-986016 Drug Profile2272
  BNV-003 Drug Profile2291
  buparlisib hydrochloride Drug Profile2305
  cabazitaxel Drug Profile2352
  capmatinib Drug Profile2373
  CB-1158 Drug Profile2402
  Cellular Immunotherapy for Oncology Drug Profile2421
  Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile2431
  Cellular Immunotherapy to Target MAGE-A10 for Oncology Drug Profile2442
  cetuximab Drug Profile2466
  cetuximab biobetter Drug Profile2522
  cetuximab biosimilar Drug Profile2541
  cetuximab biosimilar Drug Profile2551
  cetuximab biosimilar Drug Profile2561
  cetuximab biosimilar Drug Profile2571
  cetuximab biosimilar Drug Profile2581
  cetuximab biosimilar Drug Profile2591
  cisplatin Drug Profile2602
  copanlisib hydrochloride Drug Profile2624
  COTI-2 Drug Profile2668
  CYT-6091 Drug Profile2742
  dalantercept Drug Profile2764
  Debio-1143 Drug Profile2803
  depatuxizumab Drug Profile2831
  DNA IL-12 Drug Profile2848
  DPV-001 Drug Profile2922
  DTP-348 Drug Profile2941
  durvalumab Drug Profile29511
  durvalumab + tremelimumab Drug Profile3064
  E-10A Drug Profile3101
  E-7046 Drug Profile3111
  EBC-46 Drug Profile3121
  EDC-2 Drug Profile3131
  EDE-1409 Drug Profile3141
  enoblituzumab Drug Profile3152
  epacadostat Drug Profile3175
  ETBX-041 Drug Profile3221
  everolimus Drug Profile32311
  ficlatuzumab Drug Profile3343
  futuximab + modotuximab Drug Profile3373
  ganetespib Drug Profile34012
  gedatolisib Drug Profile3522
  Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma Drug Profile3541
  GL-0817 Drug Profile3551
  glesatinib Drug Profile3565
  golvatinib tartrate Drug Profile3612
  GS-10 Drug Profile3632
  GSK-2636771 Drug Profile3651
  GSK-2849330 Drug Profile3661
  GSK-3174998 Drug Profile3671
  GX-051 Drug Profile3681
  HF-10 Drug Profile3692
  HSV-1716 Drug Profile3713
  human papillomavirus [serotypes 16] vaccine Drug Profile3741
  HylaPlat Drug Profile3751
  IC-1001 Drug Profile3761
  INCB-50465 Drug Profile3771
  INO-1400 Drug Profile3781
  INO-3106 Drug Profile3791
  INO-3112 Drug Profile3802
  interferon gamma-1b Drug Profile3824
  IPI-549 Drug Profile3862
  ipilimumab Drug Profile3889
  IRX-2 Drug Profile3972
  itacitinib adipate Drug Profile3993
  JS-001 Drug Profile4021
  JX-929 Drug Profile4031
  Kevetrin Drug Profile40411
  KGP-94 Drug Profile4151
  KTN-3379 Drug Profile4164
  lenvatinib mesylate Drug Profile42013
  Leukocyte Interleukin Drug Profile43314
  LGK-974 Drug Profile4471
  lirilumab Drug Profile4484
  LN-145 Drug Profile4522
  LOXO-101 Drug Profile4544
  lumretuzumab Drug Profile4582
  masitinib Drug Profile46014
  MEDI-0562 Drug Profile4742
  merestinib Drug Profile4762
  MGD-009 Drug Profile4782
  MIR-101 Drug Profile4801
  monalizumab Drug Profile4814
  Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma Drug Profile4851
  motolimod Drug Profile4863
  MP-0250 Drug Profile4891
  nilotinib Drug Profile4906
  nimotuzumab Drug Profile4964
  nivolumab Drug Profile50033
  NIZ-985 Drug Profile5331
  NP-001 Drug Profile5341
  olaparib Drug Profile5359
  Oncolytic Virus 1 to Target CD46 for Oncology Drug Profile5441
  Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma Drug Profile5451
  palbociclib Drug Profile54611
  panitumumab Drug Profile5575
  patritumab Drug Profile5622
  pelareorep Drug Profile56414
  pembrolizumab Drug Profile57837
  PF-04518600 Drug Profile6151
  PF-06801591 Drug Profile6161
  picoplatin Drug Profile6173
  poziotinib Drug Profile6202
  prexasertib Drug Profile6222
  QR-206 Drug Profile6241
  Recombinant Peptide to Target EGFR for Oncology Drug Profile6251
  Recombinant Protein for Oncology Drug Profile6261
  rigosertib sodium Drug Profile62710
  S-488210 Drug Profile6371
  sacituzumab Drug Profile6388
  SB-01 Drug Profile6461
  seribantumab Drug Profile6477
  SF-1126 Drug Profile6542
  Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile6561
  Small Molecules to Antagonize Endothelin B Receptor for Oncology Drug Profile6571
  Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma, Malaria and Oral Cancer Drug Profile6581
  Small Molecules to Inhibit CREB Protein for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile6591
  Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma Drug Profile6601
  solarise Drug Profile6611
  Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile6621
  TAK-659 Drug Profile6631
  talimogene laherparepvec Drug Profile6646

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016" Nov 09, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Head-And-Neck-Cancer-Squamous-Cell-Carcinoma-Pipeline-Review-H2-2016-2088-16766>
  
APA:
Global Markets Direct - Market Research. (2016). Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016 Nov 09, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Head-And-Neck-Cancer-Squamous-Cell-Carcinoma-Pipeline-Review-H2-2016-2088-16766>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.